Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86676
Title:
Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance.
Authors:
Wrigley, E; Verspaget, H W; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; McGown, Alan T
Abstract:
BACKGROUND AND PURPOSE: Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. METHODS: Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. RESULTS: An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. CONCLUSION: These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein.
Affiliation:
CRC Department of Drug Development, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester M20 4BX, United Kingdom.
Citation:
Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. 2000, 126 (12):717-21 J. Cancer Res. Clin. Oncol.
Journal:
Journal of Cancer Research and Clinical Oncology
Issue Date:
Dec-2000
URI:
http://hdl.handle.net/10541/86676
DOI:
10.1007/PL00008477
PubMed ID:
11153145
Type:
Article
Language:
en
ISSN:
0171-5216
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorWrigley, Een
dc.contributor.authorVerspaget, H Wen
dc.contributor.authorJayson, Gordon Cen
dc.contributor.authorMcGown, Alan Ten
dc.date.accessioned2009-11-23T11:05:27Z-
dc.date.available2009-11-23T11:05:27Z-
dc.date.issued2000-12-
dc.identifier.citationMetallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. 2000, 126 (12):717-21 J. Cancer Res. Clin. Oncol.en
dc.identifier.issn0171-5216-
dc.identifier.pmid11153145-
dc.identifier.doi10.1007/PL00008477-
dc.identifier.urihttp://hdl.handle.net/10541/86676-
dc.description.abstractBACKGROUND AND PURPOSE: Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. METHODS: Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. RESULTS: An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. CONCLUSION: These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subjectBiological Tumour Markersen
dc.subjectCancerous Gene Expression Regulationen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarcinoma-
dc.subject.meshDisease-Free Survival-
dc.subject.meshFemale-
dc.subject.meshFrozen Sections-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshHumans-
dc.subject.meshMetallothionein-
dc.subject.meshMiddle Aged-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPlatinum Compounds-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshPrognosis-
dc.subject.meshRadioimmunoassay-
dc.subject.meshReoperation-
dc.subject.meshRisk Factors-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.subject.meshTumor Markers, Biological-
dc.titleMetallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Drug Development, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester M20 4BX, United Kingdom.en
dc.identifier.journalJournal of Cancer Research and Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.